Comparison of the glycosylation of in vitro generated polyclonal human IgG and therapeutic immunoglobulins

Molecular Immunology

Volumn 57, Issue 2, 2014, Pages 255-262

  Ritamo, Ilja ^a   Cloutier, Marc ^b   Valmu, Leena ^a,d   Néron, Sonia ^b,c   Räbinä, Jarkko ^a  

^a FINNISH RED CROSS BLOOD SERVICE   (Finland)

^b HÉMA QUÉBEC   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d Thermo Fisher Scientific Oy   (Finland)

Author keywords

Antibody; Fc receptor; Glycosylation; IgG; Mass spectrometry

Indexed keywords

FC RECEPTOR; GLYCAN; GLYCOPEPTIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; N ACETYLGLUCOSAMINE; N ACETYLNEURAMINIC ACID; POLYCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FUCOSYLATION; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEMORY CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIALYLATION;

EID: 84886998928     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.10.005     Document Type: Article

References (38)

1. Anon., 2009. (accessed 07.06.13). http://www.proglycan.com/upload/IgG_Table_Rosetta.pdf.
2. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 5874:373-376.
3. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 1:21-50.
4. Borys M.C., Dalal N.G., Abu-Absi N.R., Khattak S.F., Jing Y., Xing Z., Li Z.J. Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol. Bioeng. 2010, 6:1048-1057.
5. Bosques C.J., Collins B.E., Meador J.W., Sarvaiya H., Murphy J.L., Dellorusso G., Bulik D.A., Hsu I.H., Washburn N., Sipsey S.F., Myette J.R., Raman R., Shriver Z., Sasisekharan R., Venkataraman G. Chinese hamster ovary cells can produce galactose-alpha-1,3-galactose antigens on proteins. Nat. Biotechnol. 2010, 11:1153-1156.
6. Boyd P.N., Lines A.C., Patel A.K. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 1995, 17-18:1311-1318.
7. Ducas E., Dussault N., Roy A., Dumont N., Néron S. Estimation of the number of CD154 molecules in membrane extracts used as a source of CD40 stimulation of human B lymphocytes. J. Immunol. Methods 2009, 2:133-137.
8. Durandy A., Kaveri S.V., Kuijpers T.W., Basta M., Miescher S., Ravetch J.V., Rieben R. Intravenous immunoglobulins - understanding properties and mechanisms. Clin. Exp. Immunol. 2009, 2-13.
9. Fecteau J.F., Roy A., Néron S. Peripheral blood CD27(+) IgG(+) B cells rapidly proliferate and differentiate into immunoglobulin-secreting cells after exposure to low CD154 interaction. Immunology 2009, 1(Pt 2):e353-e365.
10. Ferrara C., Brunker P., Suter T., Moser S., Puntener U., Umaña P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. 2006, 5:851-861.
11. Ghaderi D., Taylor R.E., Padler-Karavani V., Diaz S., Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 2010, 8:863-867.
12. Hodoniczky J., Zheng Y.Z., James D.C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 2005, 6:1644-1652.
13. Iida S., Kuni-Kamochi R., Mori K., Misaka H., Inoue M., Okazaki A., Shitara K., Satoh M. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 2009, 58.
14. Jefferis R. Glycosylation of antibody therapeutics: optimisation for purpose. Methods Mol. Biol. 2009, 223-238.
15. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 5787:670-673.
16. Kumpel B.M., Rademacher T.W., Rook G.A., Williams P.J., Wilson I.B. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum. Antibodies Hybridomas 1994, 3-4:143-151.
17. Lifely M.R., Hale C., Boyce S., Keen M.J., Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995, 8:813-822.
18. Monica T.J., Goochee C.F., Maiorella B.L. Comparative biochemical characterization of a human IgM produced in both ascites and in vitro cell culture. Biotechnology (N Y) 1993, 4:512-515.
19. Néron S., Pelletier A., Chevrier M.C., Monier G., Lemieux R., Darveau A. Induction of LFA-1 independent human B cell proliferation and differentiation by binding of CD40 with its ligand. Immunol. Invest. 1996, 1-2:79-89.
20. Néron S., Racine C., Roy A., Guérin M. Differential responses of human B-lymphocyte subpopulations to graded levels of CD40-CD154 interaction. Immunology 2005, 4:454-463.
21. Néron S., Roy A., Dumont N. Large-scale in vitro expansion of polyclonal human switched-memory B lymphocytes. PLoS ONE 2012, 12:e51946.
22. Néron S., Roy A., Dumont N., Dussault N. Effective in vitro expansion of CD40-activated human B lymphocytes in a defined bovine protein-free medium. J. Immunol. Methods 2011, 1-2:61-69.
23. Néron S., Thibault L., Dussault N., CÔté G., Ducas E., Pineault N., Roy A. Characterization of mononuclear cells remaining in the leukoreduction system chambers of apheresis instruments after routine platelet collection: a new source of viable human blood cells. Transfusion (Paris) 2007, 6:1042-1049.
24. Oefner C.M., Winkler A., Hess C., Lorenz A.K., Holecska V., Huxdorf M., Schommartz T., Petzold D., Bitterling J., Schoen A.L., Stoehr A.D., Vu Van D., Darcan-Nikolaisen Y., Blanchard V., Schmudde I., Laumonnier Y., Ströver H.A., Hegazy A.N., Eiglmeier S., Schoen C.T., Mertes M.M., Loddenkemper C., Löhning M., König P., Petersen A., Luger E.O., Collin M., Köhl J., Hutloff A., Hamelmann E., Berger M., Wardemann H., Ehlers M. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J. Allergy Clin. Immunol. 2012, 6:1647-1655. e13.
25. Padet L., St-Amour I., Aubin E., Bazin R. Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?. Clin. Exp. Immunol. 2011, 3:352-360.
26. Parekh R.B., Dwek R.A., Sutton B.J., Fernandes D.L., Leung A., Stanworth D., Rademacher T.W., Mizuochi T., Taniguchi T., Matsuta K. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985, 6027:452-457.
27. Peltoniemi H., Natunen S., Ritamo I., Valmu L., Räbinä J. Novel data analysis tool for semiquantitative LC-MS-MS2 profiling of N-glycans. Glycoconj. J. 2013, 2:159-170.
28. Raju T.S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 2008, 4:471-478.
29. Rezaei N., Abolhassani H., Aghamohammadi A., Ochs H.D. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev. Clin. Immunol. 2011, 3:301-316.
30. Ritamo I., Räbinä J., Natunen S., Valmu L. Nanoscale reversed-phase liquid chromatography-mass spectrometry of permethylated N-glycans. Anal. Bioanal. Chem. 2013, 8:2469-2480.
31. Scherer H.U., Burmester G.R. A clinical perspective of rheumatoid arthritis. Eur. J. Immunol. 2009, 8:2044-2048.
32. Scherer H.U., van der Woude D., Ioan-Facsinay A., el Bannoudi H., Trouw L.A., Wang J., Haupl T., Burmester G.R., Deelder A.M., Huizinga T.W., Wuhrer M., Toes R.E. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 2010, 6:1620-1629.
33. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 30:26733-26740.
34. Stadlmann J., Weber A., Pabst M., Anderle H., Kunert R., Ehrlich H.J., Peter Schwarz H., Altmann F. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 2009, 17:4143-4153.
35. The UniProt Consortium Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res. 2012, D1:D71-D75.
36. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 9:917-924.
37. Wang J., Balog C.I., Stavenhagen K., Koeleman C.A., Scherer H.U., Selman M.H., Deelder A.M., Huizinga T.W., Toes R.E., Wuhrer M. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol. Cell. Proteomics 2011, 5. M110.004655.
38. Wuhrer M., Porcelijn L., Kapur R., Koeleman C.A., Deelder A., de Haas M., Vidarsson G. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J. Proteome Res. 2009, 2:450-456.